SCHEMBL24904303

SCHEMBL24904303

O=C1NC(Nc2ccccc2)=N/C1=C\c1ccc2[nH]cnc2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 18/20 0.64
▸ DYRK2 Q92630 15/20 0.64
▸ DYRK1B Q9Y463 14/20 0.64
▸ DYRK3 O43781 13/20 0.64
▸ CSNK2A2 P19784 9/20 0.64
▸ CSNK2B P67870 9/20 0.64
▸ CSNK2A1 P68400 9/20 0.64
▸ CSNK2A3 Q8NEV1 9/20 0.64
▸ PIM1 P11309 9/20 0.64
▸ CLK1 P49759 5/20 0.62
▸ CLK2 P49760 5/20 0.62
▸ CLK3 P49761 5/20 0.62
▸ CLK4 Q9HAZ1 5/20 0.62
▸ DYRK4 Q9NR20 5/20 0.62
▸ GSK3B P49841 4/20 0.62
▸ CNR1 P21554 4/20 0.60
▸ GSK3A P49840 2/20 0.59
▸ CCNT1 O60563 1/20 0.59
▸ CDK9 P50750 1/20 0.59
▸ IRAK1 P51617 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28842923 1.00 DYRK1A (0.64) DYRK1ADYRK2DYRK1BDYRK3CSNK2A2
SCHEMBL29899861 1.00 DYRK1A (0.64) DYRK1ADYRK2DYRK1BDYRK3CSNK2A2
SCHEMBL26101027 0.91 DYRK1A (0.66) DYRK1ADYRK2DYRK1BDYRK3CSNK2A2
SCHEMBL26095593 0.86 DYRK1A (0.49) DYRK1ADYRK2DYRK1BDYRK3CSNK2A2
SCHEMBL30494270 0.86 DYRK1A (0.49) DYRK1ADYRK2DYRK1BDYRK3CSNK2A2
SCHEMBL29899866 0.83 DYRK1A (0.69) DYRK1ADYRK2DYRK1BDYRK3CSNK2A2
SCHEMBL24904262 0.83 DYRK1A (0.69) DYRK1ADYRK2DYRK1BDYRK3CSNK2A2
SCHEMBL30494198 0.82 DYRK2 (0.69) DYRK1ADYRK2DYRK1BDYRK3CSNK2A2
SCHEMBL26093411 0.82 DYRK2 (0.69) DYRK1ADYRK2DYRK1BDYRK3CSNK2A2
SCHEMBL23510769 0.81 DYRK1A (0.65) DYRK1ADYRK2DYRK1BDYRK3CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114929690-B Novel heterocyclic derivatives having cardiomyocyte proliferative activity for the treatment of heart disease 同济大学 2023-05-05 — — CN disclosed
WO-2023072966-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-05-04 — — WO disclosed
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TONGJI UNIVERSITY (CN) 2023-01-26 — — US disclosed
CN-114929690-A Novel heterocyclic derivatives with cardiomyocyte proliferative activity for the treatment of cardiac diseases 同济大学 2022-08-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TNNI3, TNNT2, MKI67 DYRK1A 3319/4885DYRK2 3594/4885DYRK1B 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback